Roth Capital analyst Chris Lewis remains neutral on molecular diagnostics company EXACT Sciences Corporation (NASDAQ:EXAS). Following solid second quarter earnings results, but with …
In a research report released Friday, Roth Capital analyst Chris Lewis reiterated a Neutral rating on shares of EXACT Sciences Corporation (NASDAQ:EXAS), while raising the …
In a research report published Wednesday, Roth Capital analyst Chris Lewis reiterated a Neutral rating on shares of EXACT Sciences Corporation (NASDAQ:EXAS), with …
In a research report released today, Roth Capital analyst Chris Lewis reiterated a Buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS), while reducing …
Roth Capital analyst Chris Lewis weighed in today with a few insights on Exact Sciences Corporation (NASDAQ:EXAS), after the company held its investor & analyst day on June 25. …
Exact Sciences Corporation (NASDAQ:EXAS) shares are up 9% today after Anthem Blue Cross announced a positive coverage decision for Exact’s Cologuard test. Anthem is the largest …
Roth Capital’s healthcare analyst Chris Lewis weighed in today with a research report on Enteromedics Inc. (NASDAQ:ETRM), reiterating a Buy rating and reducing the price target …
In a research report sent to investors, Roth Capital analyst Chris Lewis reiterated a Buy rating on Nanosphere (NASDAQ:NSPH), but reduced the price …
In a research report issued today, Roth Capital analyst Chris Lewis maintained a Buy rating on EnteroMedics Inc (NASDAQ:ETRM) with a $3 price target, as …
Roth Capital analyst Chris Lewis came out today with an update on Exact Sciences Corp (NASDAQ:EXAS), as the company is in the stage of commercialization of …